Subtopic Deep Dive
Mesothelioma Immunotherapy
Research Guide
What is Mesothelioma Immunotherapy?
Mesothelioma immunotherapy encompasses immune checkpoint inhibitors, CAR T-cell therapies, and immunotoxins targeting mesothelin in malignant pleural and peritoneal mesothelioma.
Clinical trials demonstrate efficacy of nivolumab plus ipilimumab in relapsed malignant pleural mesothelioma (Scherpereel et al., 2019, 445 citations). Regional mesothelin-targeted CAR T-cell therapy combined with pembrolizumab shows promise in phase I for pleural diseases (Adusumilli et al., 2021, 503 citations). Anti-mesothelin immunotoxin SS1P established safety in phase I for mesothelin-expressing mesothelioma (Hassan et al., 2007, 378 citations). Over 2,700 citations across 10 key papers.
Why It Matters
Checkpoint inhibitors like nivolumab and ipilimumab extend progression-free survival in chemotherapy-refractory mesothelioma patients (Scherpereel et al., 2019). CAR T-cell therapy targets mesothelin in pleural mesothelioma, addressing unmet needs in aggressive tumors (Adusumilli et al., 2021). Immunotoxins such as SS1P provide targeted cytotoxicity for mesothelin-overexpressing cancers, informing combination strategies with PD-1 blockade (Hassan et al., 2007). These advances shift treatment paradigms for asbestos-related occupational lung cancers.
Key Research Challenges
Limited Response Durability
Checkpoint inhibitors achieve 20-30% response rates but most patients relapse within 6-12 months (Scherpereel et al., 2019). CAR T-cell persistence in pleural spaces remains short, limiting efficacy (Adusumilli et al., 2021).
Biomarker Identification
No validated predictive biomarkers exist for immunotherapy response in mesothelioma despite BAP1 alterations (Hmeljak et al., 2018). Mesothelin expression varies, complicating patient selection (Hassan et al., 2007).
Combination Toxicity
Nivolumab-ipilimumab causes grade 3-4 immune-related adverse events in 25% of patients (Scherpereel et al., 2019). CAR T with pembrolizumab elevates cytokine release syndrome risks (Adusumilli et al., 2021).
Essential Papers
Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy for Malignant Peritoneal Mesothelioma: Multi-Institutional Experience
Tristan D. Yan, Marcello Deraco, Dario Baratti et al. · 2009 · Journal of Clinical Oncology · 675 citations
Purpose This multi-institutional registry study evaluated cytoreductive surgery (CRS) combined with hyperthermic intraperitoneal chemotherapy (HIPEC) for diffuse malignant peritoneal mesothelioma (...
Malignant mesothelioma
Bruce Robinson, Arthur W. Musk, Richard Lake · 2005 · The Lancet · 663 citations
Randomized Phase III Study of Cisplatin With or Without Raltitrexed in Patients With Malignant Pleural Mesothelioma: An Intergroup Study of the European Organisation for Research and Treatment of Cancer Lung Cancer Group and the National Cancer Institute of Canada
Jan P. van Meerbeeck, Rabab Gaafar, Christian Manegold et al. · 2005 · Journal of Clinical Oncology · 621 citations
Purpose We conducted a phase III trial to determine whether first-line treatment with raltitrexed, a thymidine synthase inhibitor, and cisplatin results in superior outcome compared with cisplatin ...
Integrative Molecular Characterization of Malignant Pleural Mesothelioma
Julija Hmeljak, Francisco Sánchez-Vega, Katherine A. Hoadley et al. · 2018 · Cancer Discovery · 578 citations
Abstract Malignant pleural mesothelioma (MPM) is a highly lethal cancer of the lining of the chest cavity. To expand our understanding of MPM, we conducted a comprehensive integrated genomic study,...
Management of malignant pleural effusions
Veena B. Antony, R. Loddenkemper, P. Astoul et al. · 2001 · European Respiratory Journal · 525 citations
⇓Malignant pleural effusions are a common clinical problem in patients with neoplastic disease. In one post mortem series, malignant effusions were found in 15% of patients who died with malignanci...
A Phase I Trial of Regional Mesothelin-Targeted CAR T-cell Therapy in Patients with Malignant Pleural Disease, in Combination with the Anti–PD-1 Agent Pembrolizumab
Prasad S. Adusumilli, Marjorie G. Zauderer, Isabelle Rivière et al. · 2021 · Cancer Discovery · 503 citations
Abstract Malignant pleural diseases, comprising metastatic lung and breast cancers and malignant pleural mesothelioma (MPM), are aggressive solid tumors with poor therapeutic response. We developed...
Nivolumab or nivolumab plus ipilimumab in patients with relapsed malignant pleural mesothelioma (IFCT-1501 MAPS2): a multicentre, open-label, randomised, non-comparative, phase 2 trial
Arnaud Scherpereel, Julien Mazières, Laurent Greillier et al. · 2019 · The Lancet Oncology · 445 citations
Reading Guide
Foundational Papers
Read Hassan et al. (2007) first for mesothelin immunotoxin proof-of-concept (378 citations), then Robinson et al. (2005) for mesothelioma immunology overview (663 citations), and van Meerbeeck et al. (2005) for chemotherapy baseline (621 citations).
Recent Advances
Study Scherpereel et al. (2019) for checkpoint inhibitor efficacy (445 citations) and Adusumilli et al. (2021) for CAR T advances (503 citations); Hmeljak et al. (2018) details molecular targets (578 citations).
Core Methods
Core techniques: checkpoint blockade (anti-PD-1), adoptive CAR T-cell therapy (mesothelin-targeted), immunotoxins (SS1P dsFv-PE38), combined with pembrolizumab or chemotherapy (Scherpereel et al., 2019; Adusumilli et al., 2021; Hassan et al., 2007).
How PapersFlow Helps You Research Mesothelioma Immunotherapy
Discover & Search
Research Agent uses searchPapers and exaSearch to retrieve immunotherapy trials, then citationGraph reveals Scherpereel et al. (2019) as a 445-citation hub connecting nivolumab-ipilimumab studies to Adusumilli et al. (2021) CAR T work; findSimilarPapers expands to mesothelin-targeted therapies.
Analyze & Verify
Analysis Agent applies readPaperContent to extract trial endpoints from Scherpereel et al. (2019), verifies response rates via verifyResponse (CoVe) against raw data, and runs PythonAnalysis for Kaplan-Meier survival curve meta-analysis with GRADE grading of phase II evidence.
Synthesize & Write
Synthesis Agent detects gaps in biomarker validation across trials, flags contradictions between SS1P toxicity and CAR T safety (Hassan et al., 2007 vs. Adusumilli et al., 2021); Writing Agent uses latexEditText, latexSyncCitations, and latexCompile to generate review manuscripts with exportMermaid for immunotherapy workflow diagrams.
Use Cases
"Extract and plot survival data from nivolumab mesothelioma trials"
Research Agent → searchPapers → Analysis Agent → readPaperContent (Scherpereel 2019) → runPythonAnalysis (pandas survival curves, matplotlib PFS/OS plots) → researcher gets CSV-exported meta-analysis with GRADE scores.
"Draft LaTeX review on CAR T for pleural mesothelioma"
Synthesis Agent → gap detection → Writing Agent → latexEditText (structure sections) → latexSyncCitations (Adusumilli 2021) → latexCompile → researcher gets PDF manuscript with embedded trial timelines.
"Find code for mesothelin CAR T analysis pipelines"
Research Agent → citationGraph (Adusumilli 2021) → Code Discovery → paperExtractUrls → paperFindGithubRepo → githubRepoInspect → researcher gets annotated Python scripts for T-cell sequencing analysis.
Automated Workflows
Deep Research workflow conducts systematic review of 50+ mesothelioma immunotherapy papers via searchPapers → citationGraph → DeepScan 7-step verification, yielding structured report with GRADE-graded evidence tables. Theorizer generates hypotheses on mesothelin-PD1 combinations from Scherpereel (2019) and Adusumilli (2021) via gap detection → contradiction flagging. Chain-of-Verification/CoVe ensures zero hallucinations in biomarker synthesis.
Frequently Asked Questions
What defines mesothelioma immunotherapy?
Mesothelioma immunotherapy includes checkpoint inhibitors (nivolumab/ipilimumab), CAR T-cells targeting mesothelin, and immunotoxins like SS1P (Scherpereel et al., 2019; Adusumilli et al., 2021; Hassan et al., 2007).
What are key methods in mesothelioma immunotherapy?
Methods encompass anti-PD-1/PD-L1 blockade (nivolumab), dual checkpoint inhibition (nivolumab+ipilimumab), regional CAR T infusion with pembrolizumab, and mesothelin-specific immunotoxins (Scherpereel et al., 2019; Adusumilli et al., 2021; Hassan et al., 2007).
What are the most cited papers?
Top papers: Scherpereel et al. (2019, 445 citations, nivolumab trial); Adusumilli et al. (2021, 503 citations, CAR T); Hassan et al. (2007, 378 citations, SS1P immunotoxin).
What open problems exist?
Challenges include poor response durability, lack of biomarkers, and combination toxicities; no phase III CAR T data and unclear BAP1 role in immunotherapy (Scherpereel et al., 2019; Adusumilli et al., 2021; Hmeljak et al., 2018).
Research Occupational and environmental lung diseases with AI
PapersFlow provides specialized AI tools for Medicine researchers. Here are the most relevant for this topic:
Systematic Review
AI-powered evidence synthesis with documented search strategies
AI Literature Review
Automate paper discovery and synthesis across 474M+ papers
Find Disagreement
Discover conflicting findings and counter-evidence
Paper Summarizer
Get structured summaries of any paper in seconds
See how researchers in Health & Medicine use PapersFlow
Field-specific workflows, example queries, and use cases.
Start Researching Mesothelioma Immunotherapy with AI
Search 474M+ papers, run AI-powered literature reviews, and write with integrated citations — all in one workspace.
See how PapersFlow works for Medicine researchers